Related references
Note: Only part of the references are listed.Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients
M. Veny et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management
Signe Larsen et al.
ANNALS OF MEDICINE (2010)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Adalimumab Safety in Global Clinical Trials of Patients with Crohn's Disease
Jean-Frederic Colombel et al.
INFLAMMATORY BOWEL DISEASES (2009)
Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone
Eva Zold et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease
S. Kugathasan et al.
GUT (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Extraintestinal manifestations of Crohn's disease
Pascal Juillerat et al.
DIGESTION (2007)
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
TN Brooklyn et al.
GUT (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
The effect of infliximab on extraintestinal manifestations of Crohn's disease
I Kaufman et al.
RHEUMATOLOGY INTERNATIONAL (2005)
Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations
S Generini et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Dermatologic manifestations of Crohn disease in children: Response to infliximab
S Kugathasan et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2003)
Response of cutaneous Crohn's disease to infliximab and methotrexate
A Konrad et al.
DIGESTIVE AND LIVER DISEASE (2003)
Inflammatory bowel disease
DK Podolsky
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Long-term evolution of disease behavior of Crohn's disease
J Cosnes et al.
INFLAMMATORY BOWEL DISEASES (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
